Pre-made Talquetamab benchmark antibody ( Bispecific mAb, anti-GPRC5D;CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-546

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-546 Category Tags ,

Product Details

Pre-Made Talquetamab biosimilar, Bispecific mAb, Anti-GPRC5D;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Talquetamab is a humanized IgG4PAA bispecific antibody designed to target G protein-coupled receptor family C group 5-member D (GPRC5D) and the CD3 molecule found on T lymphocytes (T cell).

Products Name (INN Index)

Pre-Made Talquetamab biosimilar, Bispecific mAb, Anti-GPRC5D;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody

INN Name

Talquetamab

Target

GPRC5D,CD3E

Format

Bispecific mAb

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa,Lambda

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2019

Companies

Genmab,Janssen Research & Development

Conditions Approved

NA

Conditions Active

Multiple myeloma

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

GPRC5D,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide